Vascular Endothelial Growth Factor A
"Vascular Endothelial Growth Factor A" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The original member of the family of endothelial cell growth factors referred to as VASCULAR ENDOTHELIAL GROWTH FACTORS. Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as "tumor angiogenesis factor" and "vascular permeability factor". Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating VASODILATION via NITRIC OXIDE-dependent pathways. Alternative splicing of the mRNA for vascular endothelial growth factor A results in several isoforms of the protein being produced.
| Descriptor ID |
D042461
|
| MeSH Number(s) |
D12.644.276.100.800.200 D12.776.467.100.800.200 D23.529.100.800.200
|
| Concept/Terms |
Vascular Endothelial Growth Factor A- Vascular Endothelial Growth Factor A
- Vascular Endothelial Growth Factor-A
- VEGF-A
- Vasculotropin
- VEGF
- Vascular Endothelial Growth Factor
- Vascular Permeability Factor
- Permeability Factor, Vascular
|
Below are MeSH descriptors whose meaning is more general than "Vascular Endothelial Growth Factor A".
Below are MeSH descriptors whose meaning is more specific than "Vascular Endothelial Growth Factor A".
This graph shows the total number of publications written about "Vascular Endothelial Growth Factor A" by people in this website by year, and whether "Vascular Endothelial Growth Factor A" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 3 | 3 |
| 1999 | 0 | 7 | 7 |
| 2000 | 0 | 5 | 5 |
| 2001 | 0 | 7 | 7 |
| 2002 | 0 | 6 | 6 |
| 2003 | 0 | 3 | 3 |
| 2004 | 4 | 4 | 8 |
| 2005 | 5 | 7 | 12 |
| 2006 | 0 | 3 | 3 |
| 2007 | 7 | 5 | 12 |
| 2008 | 5 | 10 | 15 |
| 2009 | 4 | 6 | 10 |
| 2010 | 2 | 6 | 8 |
| 2011 | 4 | 12 | 16 |
| 2012 | 5 | 8 | 13 |
| 2013 | 10 | 4 | 14 |
| 2014 | 9 | 10 | 19 |
| 2015 | 3 | 6 | 9 |
| 2016 | 5 | 3 | 8 |
| 2017 | 6 | 7 | 13 |
| 2018 | 3 | 4 | 7 |
| 2019 | 1 | 8 | 9 |
| 2020 | 3 | 3 | 6 |
| 2021 | 4 | 5 | 9 |
| 2022 | 1 | 7 | 8 |
| 2023 | 2 | 10 | 12 |
| 2024 | 3 | 6 | 9 |
| 2025 | 5 | 2 | 7 |
| 2026 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vascular Endothelial Growth Factor A" by people in Profiles.
-
Peri-Event Intravitreal Anti-VEGF and Systemic Outcomes After Stroke or Myocardial Infarction. JAMA Ophthalmol. 2026 05 01; 144(5):415-422.
-
Development of Miniprotein Binders to Inhibit VEGF-Induced Corneal Neovascularization. Invest Ophthalmol Vis Sci. 2026 05 01; 67(5):61.
-
Fluocinolone Acetonide Implant as a Baseline Therapy for Diabetic Macular Edema: Results from the Randomized Phase 4 NEW DAY Study. Ophthalmology. 2026 Jul; 133(7):837-851.
-
Novel targets beyond vascular endothelial growth factor-A inhibition: improving vision with neovascular age-related macular degeneration treatment. Eye (Lond). 2025 Dec; 39(17):3045-3057.
-
The splicing factor kinase SRPK1 is a therapeutic target for peripheral vascular disease. Am J Physiol Heart Circ Physiol. 2025 08 01; 329(2):H490-H504.
-
Short-term effects of tetracycline use in patients with diabetic retinopathy. Can J Ophthalmol. 2025 12; 60(6):e858-e868.
-
Sustained ROS scavenging and pericellular oxygenation by lignin composites rescue HIF-1a and VEGF levels to improve diabetic wound neovascularization and healing. Acta Biomater. 2025 08; 202:205-215.
-
A potential VEGF-driven hypothesis of calvarial centripetal proliferation in cerebral proliferative angiopathy. Sci Rep. 2025 01 20; 15(1):2502.
-
Suppression of matrigel-induced choroidal neovascularization by AAV delivery of a novel anti-Scg3 antibody. Gene Ther. 2024 11; 31(11-12):587-593.
-
Pravastatin Protects Cytotrophoblasts from Hyperglycemia-Induced Preeclampsia Phenotype. Cells. 2024 09 13; 13(18).